Compass Therapeutics (CMPX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of two class III directors to serve until the 2029 annual meeting, with nominees Thomas J. Schuetz, M.D., Ph.D., and Richard S. Lindahl, M.B.A.
Ratification of CohnReznick LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve the compensation of named executive officers.
Advisory vote on the frequency of future advisory votes regarding executive compensation, with a recommendation for annual votes.
Proxies are authorized to vote on other business that may arise at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and auditor ratification.
Directors up for election will serve until 2029 or until a successor is duly elected and qualified.
Executive compensation and say-on-pay
Advisory vote solicited on the compensation of named executive officers.
Advisory vote solicited on the frequency of future say-on-pay votes, with a recommendation for annual votes.
Latest events from Compass Therapeutics
- Tovecimig achieved key BTC milestones as Q1 2026 net loss rose to $18.3M, with strong cash reserves.CMPX
Q1 20265 May 2026 - Tovecimig plus paclitaxel improved PFS and ORR with manageable safety in biliary tract cancer.CMPX
Study update29 Apr 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance practices.CMPX
Proxy filing29 Apr 2026 - Tovecimig achieved 17.1% ORR in 2L BTC, with pivotal data and filings expected in 2026.CMPX
Corporate presentation5 Mar 2026 - Key trial success and strong cash position set stage for pivotal 2026 milestones.CMPX
Q4 20255 Mar 2026 - Lead oncology drug 009 shows strong efficacy; pivotal trial results due early next year.CMPX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Lead antibody tovecimig achieved pivotal efficacy in biliary tract cancer, targeting U.S. launch.CMPX
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Phase 2/3 BTC study met primary endpoint with 17.1% ORR for tovecimig, PFS/OS data due Q1 2026.CMPX
Corporate presentation14 Jan 2026 - Lead bispecific antibody in BTC shows strong efficacy; pivotal data expected by Q1 next year.CMPX
Jefferies London Healthcare Conference 202412 Jan 2026